3-Oxotetrahydrofuran → (R)-4-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-8-((1-(tetrahydrofuran-3-yl)azetidin-3-yl)methyl)-9H-purin-6-yl)morpholine

HRID 1923268

Reaktionsgleichung

Reaktionsgleichung von HRID 1923268
[NH:1]1[CH2:4][CH:3]([CH2:5][C:6]2[N:7]([CH3:31])[C:8]3[C:13]([N:14]=2)=[C:12]([N:15]2[CH2:20][CH2:19][O:18][CH2:17][CH2:16]2)[N:11]=[C:10]([N:21]2[C:25]4[CH:26]=[CH:27][CH:28]=[CH:29][C:24]=4[N:23]=[C:22]2[CH3:30])[N:9]=3)[CH2:2]1.[O:32]1[CH2:36][CH2:35][C:34](=O)[CH2:33]1>>[CH3:31][N:7]1[C:6]([CH2:5][CH:3]2[CH2:2][N:1]([C@@H:34]3[CH2:35][CH2:36][O:32][CH2:33]3)[CH2:4]2)=[N:14][C:13]2[C:8]1=[N:9][C:10]([N:21]1[C:25]3[CH:26]=[CH:27][CH:28]=[CH:29][C:24]=3[N:23]=[C:22]1[CH3:30])=[N:11][C:12]=2[N:15]1[CH2:20][CH2:19][O:18][CH2:17][CH2:16]1

Komponenten

3

Edukt 2

HCID 5293923-OxotetrahydrofuranHCID 596054598-Azetidin-3-ylmethyl-2-(2-methylbenzoimidazol-1-yl)-9-methyl-6-morpholin-4-yl-9H-purine

Produkt 1

HCID 67492839(R)-4-(9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-8-((1-(tetrahydrofuran-3-yl)azetidin-3-yl)methyl)-9H-purin-6-yl)morpholine

Versuchsvorschrift

Following General Procedure L, 4-(8-(azetidin-3-ylmethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine and dihydrofuran-3(2H)-one were reacted to give the racemic mixture. The enantiomers were separated by SFC to give 573. LCMS m/z: 245.2 (2M+H+)

Aufarbeitung

  1. customwere reacted
  2. customto give the racemic mixture
  3. customThe enantiomers were separated by SFC

Quellen und Nachweise

ORD-Eintrag
ord-780ad54e4a8640e686918c865652b916
Quelldatensatz
uspto-grants-2012_05
Patentnummer
US08173650B2

Verknüpfte Notizen

Wird geladen…